Oxford based e-therapeutics appoints new Chief Financial Officer

Karl Keegan e-therapeutics

Oxford-based e-therapeutics plc has appointed appointment of Dr Karl Keegan as Chief Financial Officer effective immediately. The CFO role will be a non-board position. 

Dr Keegan brings a depth of capital market and strategic financing experience with over 20 years’ experience in the pharmaceutical and biotech industries. After working in academia and large pharma, Karl became a highly rated sell-side analyst at a number of investment banks. Since 2009, he has held senior executive roles in private and public companies, most recently as Chief Executive Officer of privately held Hox Therapeutics Limited. 

Karl received his BSc in Pharmacology from University College Dublin, MPhil and PhD degrees from the University of Cambridge and his MSc (Finance) from London Business School.

Dr Keegan, Chief Financial Officer, said: “I am delighted to be joining the e-therapeutics team at such a pivotal time for the Company. The Company has built an impressive computational biology drug discovery platform and clinically validated RNA interference drug modality.”

Ali Mortazavi, Chief Executive Officer, said: “We are delighted to welcome Karl to e-therapeutics at this point in the Company’s evolution. The combination of his industry and financial sector expertise will be a major addition to the team.”

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.